Skip to main content
Clinical Trials/NCT01707680
NCT01707680
Terminated
Not Applicable

Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients

Orion Corporation, Orion Pharma3 sites in 1 country155 target enrollmentJune 1, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Critical Illness
Sponsor
Orion Corporation, Orion Pharma
Enrollment
155
Locations
3
Primary Endpoint
The time point from when the patient is considered "fit for weaning" to the actual time point for extubation
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the use of different sedatives affect the weaning process from mechanical ventilation in intensive care patients.

Detailed Description

Traditionally patients with ongoing mechanical ventilation have been sedated to assure absence of pain, anxiety and to provide comfort. Unfortunately this approach might have negative consequences such as prolonged time for mechanical ventilation, length of stay in the ICU and hospital. In this study, the investigators would like to investigate (in an exploratory way due to the non-interventional setup) whether weaning from mechanical ventilation will be affected by the choice of sedatives - including dexmedetomidine, midazolam and propofol. This study also aims at investigating how the choice of primary sedative will affect delirium/anxiety, need of other medications (sedatives, analgesics, anti-psychotics), quality of life after ICU and the presence of Post-Traumatic Stress Disorder. In addition, the investigators aim at receiving information from the caregivers on their ICU experience, as recent data imply that not only the ICU patient but also the caregiver suffer from PTSD after the ICU stay.

Registry
clinicaltrials.gov
Start Date
June 1, 2012
End Date
November 1, 2015
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Admitted to a general ICU ward
  • ≥ 18years
  • Intubated and mechanically ventilated for at least 24 hours
  • Need of light to moderate sedation (corresponding to RASS 0 - (-3) or MAAS 2-3)
  • Sedated with dexmedetomidine, midazolam and/or propofol
  • Good knowledge in Swedish language
  • Signed informed consent
  • Exclusion criteria:
  • Lack of fulfilling prescribed sedation regime
  • Estimated high risk of death during the study period, according to investigator (roughly equal to estimated mortality rate (EMR) \> 80% )

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The time point from when the patient is considered "fit for weaning" to the actual time point for extubation

Time Frame: 30 days

Secondary Outcomes

  • Extubation failure (re-intubation within 24 hours)(24 hours)
  • Length of ICU stay (actual time of discharge)(30 days)
  • Number of days using opioids(30 days)
  • Number of days using antipsychotic/neuroleptic drugs(30 days)
  • Anxiety/delirium assessments(30 days)
  • QoL (15D)(2-4 months post-ICU discharge)
  • Post-Traumatic Stress Disorder assessment - PTSS14 questionnaire(2-4 months post-ICU discharge)
  • Total duration of sedation(30 days)
  • Time-point for patient being considered "fit for extubation"(30 days)
  • Total time in mechanical ventilation(30 days)

Study Sites (3)

Loading locations...

Similar Trials